BC Innovations | Oct 31, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers The numbers of circulating hybrid leukocyte-epithelial cells expressing PTPRC and creatine kinase could help predict survival in pancreatic cancer. In 18 patients, high numbers of the hybrid cells expressing PTPRC and creatine...
BioCentury | Nov 3, 2017
Strategy

Broadening Novartis’ NET

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease. On Oct....
BC Week In Review | Nov 11, 2016
Company News

Tyg Oncology, Cancer Research UK deal

Tyg and Cancer Research UK (CRUK) partnered to develop Tyg’s TYG100 . CRUK will conduct a Phase I trial of TYG100 to treat solid tumors. Upon completion of the trial, Tyg will have the option to...
BioCentury | Jun 15, 2015
Emerging Company Profile

Maximizing immunogenicity

OncoQR ML is developing allogeneic cancer vaccines that use S-TIR active immunotherapy technology to increase immunogenicity compared with earlier approaches. According to co-founder, Managing Director and COO Christof Langer, the company's "warhead" approach enables a...
BioCentury | Sep 23, 2013
Finance

Shiny new Perle

Shiny new Perle With the SEC rules on crowd-funding set to take effect on Sept. 23, Perle BioScience Inc. has launched a bid to raise $2 million via that process. The Type I diabetes company...
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
BC Innovations | Feb 14, 2013
Distillery Therapeutics

Indication: Genitourinary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Genitourinary disease Benign prostatic hyperplasia (BPH) Gastrin-releasing peptide (GRP) In vitro and rat studies suggest GRP antagonists could help treat BPH. In human prostate cell lines,...
BC Week In Review | Jul 2, 2012
Clinical News

Zealand Pharma preclinical data

In a mouse model of diabetes, once-daily ZP3022 led to a significant increase in beta-cell mass at week 8 vs. both liraglutide- and vehicle-treated controls. Both ZP3022 and liraglutide also significantly increased beta-cell mass at...
BC Week In Review | Jun 11, 2012
Company News

Drais, Seldar, Astellas deal

Astellas and Drais partnered to form virtual company - Seldar Pharma Inc. - that will develop and commercialize Astellas' ASP7147 for irritable bowel syndrome with diarrhea. Seldar, which will be managed by Drais' executive team, raised $13...
BC Innovations | Jun 7, 2012
Cover Story

Two-pronged approach to T1D

Researchers at the City of Hope have combined a method to regenerate pancreatic b cells with a strategy to induce immune tolerance and have used the dual approach to treat advanced type 1 diabetes in...
Items per page:
1 - 10 of 103